New drug approval: Nivolumab plus Ipilimumab/chemotherapy in esophageal squamous-cell carcinoma

被引：0
|
作者：
Chalah, Celine [1 ]
Neuzillet, Cindy [2 ]
机构：
[1] Hop St Antoine, Serv Gastroenterol, 184 Rue Faubourg St Antoine, F-75012 Paris, France
[2] Inst Curie Site St Cloud, 35 Rue Dailly, F-92210 St Cloud, France
来源：
BULLETIN DU CANCER | 2022年 / 109卷 / 10期
关键词：
Immune therapy; Anti-PD1; Anti-CTLA4; Esophageal cancer; CHEMOTHERAPY; JUNCTION; PLACEBO;
D O I：
10.1016/j.bulcan.2022.05.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：990 / 991
页数：2
相关论文
共 50 条
  • [1] Nivolumab plus chemotherapy or ipilimumab for advanced oesophageal squamous cell carcinoma
    Hindson, Jordan
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2022, 19 (04) : 216 - 216
  • [2] Nivolumab plus chemotherapy or ipilimumab for advanced oesophageal squamous cell carcinoma
    Jordan Hindson
    Nature Reviews Gastroenterology & Hepatology, 2022, 19 : 216 - 216
  • [3] Nivolumab in Esophageal Squamous-Cell Carcinoma
    Ozer, Muhammet
    Sahin, Ilyas
    Abushukair, Hassan
    Abushukair, Aya
    Saeed, Anwaar
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (20): : 1958 - 1959
  • [4] Nivolumab in Esophageal Squamous-Cell Carcinoma Reply
    Kato, Ken
    Lei, Ming
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (20): : 1961 - 1961
  • [5] NEOADJUVANT CHEMOTHERAPY-PLUS-RADIOTHERAPY FOR ESOPHAGEAL SQUAMOUS-CELL CARCINOMA
    HELLBARDT, A
    AAPRO, M
    SAPPINO, AP
    MIRIMANOFF, RO
    MEGEVAND, R
    HELVETICA CHIRURGICA ACTA, 1989, 56 (04) : 435 - 441
  • [6] Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma
    Doki, Y.
    Ajani, J. A.
    Kato, K.
    Xu, J.
    Wyrwicz, L.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C. -H.
    Adenis, A.
    El Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, M. I.
    Holtved, E.
    Ostoich, S. A.
    Kim, H. R.
    Ueno, M.
    Mansoor, W.
    Yang, W. -C.
    Liu, T.
    Bridgewater, J.
    Makino, T.
    Xynos, I.
    Liu, X.
    Lei, M.
    Kondo, K.
    Patel, A.
    Gricar, J.
    Chau, I.
    Kitagawa, Y.
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (05): : 449 - 462
  • [7] Nivolumab plus Ipilimumab Vs Platinum-Based CT plus Nivolumab In Advanced Lung Squamous-Cell Carcinoma: The Randomized SQUINT Trial
    Delmonte, A.
    Bonanno, L.
    Landi, L.
    Andrikou, K.
    Dal Maso, A.
    Minuti, G.
    Papi, M.
    Metro, G.
    Attili, I.
    Piantedosi, F.
    Pilotto, S.
    Gori, S.
    Rossi, G.
    Buglioni, S.
    Giannarelli, D.
    Cappuzzo, F.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S351 - S351
  • [8] EFFECTS OF CHEMOTHERAPY ON ULTRASTRUCTURE OF ESOPHAGEAL SQUAMOUS-CELL CARCINOMA
    ANTONAKOPOULOS, GN
    DARNTON, SJ
    NEWMAN, J
    DUFFY, JP
    MATTHEWS, HR
    HISTOPATHOLOGY, 1994, 25 (05) : 447 - 454
  • [9] Assessing Response for Nivolumab Plus Ipilimumab in Squamous Cell Carcinoma of the Head and Neck
    Klein, Oliver
    JAMA ONCOLOGY, 2024, 10 (01) : 143 - 144
  • [10] Tislelizumab plus chemotherapy for esophageal squamous cell carcinoma
    Andres, Ulrike
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2023, 61 (11):
12345